Try our Advanced Search for more refined results
In re: Prothena Corporation PLC Securities Litigation
Case Number:
1:18-cv-06425
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
October 29, 2019
Labaton, Levi & Korsinsky Seek $4.7M Fees For Prothena Suit
Prothena investors urged a New York federal court Monday to grant their attorneys at Labaton Sucharow LLP and Levi & Korsinsky LLP $4.7 million in fees and give the final go-ahead to a $15.75 million deal with the biotechnology company, resolving securities fraud claims over a clinical trial.
-
August 27, 2019
Prothena Settles Stock-Drop Suit For $15.75M
Prothena investors have negotiated a $15.75 million settlement with the neuroscience research and development company, which would end claims that it hid salient details of a clinical trial for a new drug and hurt shareholders when revelations about the trial made its stock price fall by nearly 70%.
-
September 18, 2018
Labaton, Levi Vie For Lead Role In Prothena Stock-Drop Row
Labaton Sucharow LLP and Levi & Korsinsky LLP threw their hats in the ring to be co-lead counsel in a proposed securities class action alleging Prothena cherry-picked drug trial results and lost investors more than $2 million, according to a Monday filing in New York federal court.